REFERÊNCIAS BIBLIOGRÁFICAS 163
Kantarjian HM, Talpaz M, O´Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival
benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed
chronic-phase chronic myelogenous leukemia. Blood. 2006a; 108:1835-40.
Kantarjian HM, Sawyers C, Hochhaus A, Schiffer AC, Guilhot F, Niederwiser DW, et al. Six
year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic
myeloid leukemia (CML) post interferon-A (IFN) refractoriness/intolerance. [Abstract 428].
Blood. 2006b; 108:428.
Kantarjian HM, Talpaz M, O’Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit
with imatinib mesylate theraphy in patients with accelerated-phase chronic myelogenous
leukemia−comparison with historic experience. Cancer. 2005; 103:2099-108.
Kantarjian HM, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-
dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive
chronic myeloid leukemia. Blood. 2004a; 103:2873-8.
Kantarjian H, O’Brien S, Cortes J, Giles F, Shan J, Rios MB, et al. Survival advantage with
imatinib mesylate therapy in chronic phase chronic myelogenous leukemia (CML-CP) after
IFN-α failure and in late CML-CP, comparison with historical controls. Cancer. 2004b;
10:68-75.
Kantarjian HM, Cortes JE, O’Brien S, Luthra R, Giles F, et al. Long-term survival benefit and
improved complete cytogenetic and molecular response rates with imatinib mesylate in
Philadelphia chromosome−positive chronic−phase chronic myeloid leukemia after failure of
interferon-α. Blood. 2004c; 104:1979-88.
Kantarjian HM, Cortes JE, O’Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Imatinib
mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic
myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood. 2003a; 101:97-100.
Kantarjian HM, Talpaz M, O’Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose
escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients
with chronic myelogenous leukemia. Blood. 2003b; 101:473-5.
Kantarjian HM, Schiffer CA, Sawyers CL, Hochhaus A, Guilhot F, Niederwieser DW, et al.
Imatinib maintains favorable long-term outcomes in chronic-phase myeloid leukemia (CML)
for patients failing interferon-alfa (IFN)−follow-up of a phase II study. [Abstract 3368].
Blood. 2003c; 102:3368.
Kantarjian HM, Tapaz M, Cortes J, O’Brien S, Faderl S, Thomas D, et al. Quantitative
polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate
(STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003d;
9:160-6.
Kantarjian HM, Sawyers C, Hocchaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et
al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous
leukemia. N Engl J Med. 2002; 346:645-52.